High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry
Authors:
- Nicolas MounierNMNicolas Mounier
- Carmen CanalsCCCarmen Canals
- Christian GisselbrechtCGChristian Gisselbrecht
- Jan CornelissenJCJan Cornelissen
- Roberto FoaRFRoberto Foa
- Eulogio CondeECEulogio Conde
- John MaertensJMJohn Maertens
- Michel AttalMAMichel Attal
- Alessandro RambaldiARAlessandro Rambaldi
- Charles CrawleyCCCharles Crawley
- Jian-Jian LuanJLJian-Jian Luan
- Mats BruneMBMats Brune
Open Access
- 1 May 2012
- journal article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 18 (5) , 788-793
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL StudyJournal of Clinical Oncology, 2011
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'AdulteBlood, 2010
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab EraJournal of Clinical Oncology, 2010
- Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)The Lancet Oncology, 2008
- Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trialBlood, 2008
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- High‐dose therapy and autologous stem‐cell transplantation can improve event‐free survival for indolent lymphomaCancer, 2006
- The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOPBlood, 2006
- Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s LymphomasJournal of Clinical Oncology, 2001
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995